PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsOxaliplatin
Oxaliplatin
Oxaliplatin (oxaliplatin) is a small molecule pharmaceutical. Oxaliplatin was first approved as Eloxatin on 2002-08-09. It is used to treat colorectal neoplasms, ovarian neoplasms, testicular neoplasms, and urinary bladder neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
Oxaliplatin (discontinued: Eloxatin, Oxaliplatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Oxaliplatin
Tradename
Company
Number
Date
Products
OXALIPLATINTevaN-022160 RX2009-08-07
2 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
oxaliplatinANDA2026-08-24
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01X: Other antineoplastic agents in atc
L01XA: Platinum compounds, antineoplastic drugs
L01XA03: Oxaliplatin
HCPCS
Code
Description
J9263
Injection, oxaliplatin, 0.5 mg
Clinical
Clinical Trials
3391 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD0151791815412042093929
Stomach neoplasmsD013274EFO_0003897C1680359117551547
Rectal neoplasmsD0120046026287336411
Pancreatic neoplasmsD010190EFO_0003860C2511122348128355
NeoplasmsD009369C8014015147520325
AdenocarcinomaD0002304422558217315
Colonic neoplasmsD003110C184911863428233
Neoplasm metastasisD009362EFO_00097084211831818199
Liver neoplasmsD008113EFO_1001513C22.02096481133193
Hepatocellular carcinomaD006528C22.01310745230182
Show 17 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Esophageal neoplasmsD004938C1531991113136
Large b-cell lymphoma diffuseD016403C83.3184414266
Peritoneal neoplasmsD010534152310852
RecurrenceD0120088356350
Non-small-cell lung carcinomaD0022893123149
Gallbladder neoplasmsD005706EFO_0004606C2311286241
Neoadjuvant therapyD020360221101041
Renal cell carcinomaD002292EFO_000037616192134
Esophageal squamous cell carcinomaD0000772771021934
Ovarian neoplasmsD010051EFO_0003893C5619161233
Show 73 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501218837
Bile duct neoplasmsD001650813119
Head and neck neoplasmsD006258313218
Squamous cell carcinoma of head and neckD0000771959815
Appendiceal neoplasmsD001063EFO_0003880C18.174314
Triple negative breast neoplasmsD06472684112
Ovarian epithelial carcinomaD00007721658112
Endometrial neoplasmsD016889EFO_00042306610
Transitional cell carcinomaD0022954710
MelanomaD00854510310
Show 133 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
T-cell lymphoma cutaneousD016410C84.A33
MucositisD052016EFO_1001898123
Pseudomyxoma peritoneiD011553EFO_0007456123
Skin neoplasmsD012878EFO_0004198C4422
Lymphomatoid granulomatosisD008230C83.822
Pleural effusionD010996J90112
Pleural neoplasmsD010997112
Sezary syndromeD012751C84.122
Large-cell lymphoma anaplasticD017728C84.622
Mycosis fungoidesD009182C84.022
Show 35 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Esophageal and gastric varicesD004932EFO_0009545I8544
HypertensionD006973EFO_0000537I1033
PrognosisD01137922
HemorrhageD006470MP_0001914R5822
Portal hypertensionD006975EFO_0000666K76.622
SarcopeniaD055948EFO_1000653M62.8422
Body weightD001835EFO_000433811
Plasma cell neoplasmsD05421911
Fatal outcomeD01780911
StentsD01560711
Show 21 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOxaliplatin
INNoxaliplatin
Description
Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer. It is given by injection into a vein.
Classification
Small molecule
Drug classantineoplastics (platinum derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID61825-94-3
RxCUI
ChEMBL IDCHEMBL414804
ChEBI ID
PubChem CID11947679
DrugBankDB00526
UNII ID04ZR38536J (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Oxaliplatin
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
82,312 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use